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status, yet this group is less likely to participate in screen-
ing.7 It is not known how many unscreened women make 
an informed decision not to screen, or how much non-
attendance is due to other factors.
Cervical screening delivers beneﬁ ts but can 
also cause harm
There are known risks associated with cancer screening. 
The benefi ts outweigh the risk of harm for many people. 
However, any cancer screening program will harm some 
people. A possible harm is the detection and treatment 
of inconsequential disease.9 Cervical screening detects 
lesions (dysplasia) on the cervix, which may progress to 
cervical cancer. Lesions are caused by human papilloma-
virus (HPV) infection but will not be present in all cases. 
Most infections and lesions are transient, particularly in 
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Summary
  The National Cervical Screening Program and 
associated state and territory organisations are 
responsible for promoting cervical screening. 
Communication via multiple media channels 
encourages women to be screened. However, some 
communications are not clear about the risk of cervical 
cancer and the protective capacity and reliability of the 
Pap test. The potential harms of screening are rarely 
presented. 
  Women usually receive Pap tests from general 
practitioners, who often screen opportunistically 
during appointments. Screening targets and incentive 
payments encourage high screening rates.
  Consent is an important ethical principle in the delivery 
of all health care. Provision of material information is 
one of the elements of valid consent.
  The combination of arguably ambiguous 
communications, screening participation targets and 
opportunistic testing under time pressure seems likely to 
undermine opportunities for women to be informed. 
  Of particular concern are women who are less likely to 
beneﬁ t, those who are more likely to experience harm, 
and some groups of disadvantaged women.
  Improved communications could include providing 
patients with information on the absolute risk of cervical 
cancer, and the morbidity and mortality beneﬁ ts and 
harms of screening. Screening programs internationally 
have begun providing such information.
  Areas for further research include the appropriate roles 
of the programs, screeners and individuals in providing 
and seeking information. Such work would identify the 
optimum method for informing women in the screening 
process.
Ethically sound clinical practice includes ensuring patient consent for investigations and treatments, including screening. Consent involves a competent 
individual receiving material information and advice about 
a procedure or treatment, and making a decision based 
on that information and her or his preferences and values. 
Thus, all valid consent is by defi nition informed consent,1,2 
and communication of material information is an essential 
prerequisite. What is considered material in the case of 
cervical screening will vary from woman to woman and 
will depend on her actual and perceived risk. Arguably, 
more information should be provided for procedures such 
as screening that are offered to people who are well.3 
While recognising the benefi ts of the Australian cervi-
cal screening program, we argue that current arrange-
ments may not provide the material information required 
for consent. 
Cervical screening and cervical cancer in 
Australia: an overview
Of existing cancer prevention and early detection pro-
grams, cervical screening is the least controversial. It has a 
long history, it appears to be very effective, and Australia 
has among the lowest incidence of cervical cancer in 
the world.4,5 In Australia, women aged 18–70 years are 
encouraged to screen every 2 years, an intensive pro-
gram by international standards. The National Cervical 
Screening Program (NCSP) and each state or territory 
screening program are expected to inform women of the 
service and promote it; to be screened requires a clinical 
intervention, usually involving a general practitioner. In 
April 2014, the Medical Services Advisory Committee 
made recommendations for substantial changes to the 
NCSP, refl ecting updated evidence. Subject to agreement 
from the Australian Government, changes are likely to 
be brought in from 2016, making now an excellent time 
to address any relevant ethical tensions.6
The absolute risk of a cervical cancer diagnosis is low. 
In Australia, the incidence among the screening target 
population is nine per 100 000 women per year, down 
from 17.4 per 100 000 per year in 1991, when the organised 
program began. This decline is attributed to the success 
of the program.7 The most recently reported Australian 
mortality rate is two per 100 000 women per year.
A United Kingdom estimate is that 1000 women must 
be screened once every 5 years for 35 years to avoid one 
cervical cancer death.8 Of Australian women in the target 
population with a cervix, 57% were screened in 2010–2011, 
with 83% participation over 5 years.7 Cervical cancer dis-
proportionately affects women of lower socioeconomic 
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younger women. Current screening methods are unable 
to distinguish between transient and persistent (more 
dangerous) dysplasia. As a result, screening may lead to 
treatment for lesions that would have regressed sponta-
neously. Physical harms of treating cervical lesions can 
include subsequent cervical incompetence and adverse 
perinatal outcomes.10,11 Psychological harms caused by 
abnormal screening results and associated treatments are 
well documented.12 This is not a criticism of Australia’s 
NCSP; the problem is inherent in any cervical screening 
program, arising from the natural history of the HPV 
infection. In response, the International Agency for 
Research on Cancer now recommends against screen-
ing women aged under 25 years.4
Public communications tend to overstate 
beneﬁ t and understate limitations and harms
Cervical screening programs exist to minimise the burden 
of cervical cancer in populations. This often translates 
into an objective of maximising participation. To achieve 
high uptake in the target population, screening promotion 
materials are widely used. However, they deliver mes-
sages that do not provide complete information about the 
limitations of screening, especially for younger women 
who may be at higher risk of harm because of much higher 
rates of transient HPV infection.4
A range of public promotion materials is available from 
each state or territory program and the NCSP. A sum-
mary of how key information was treated in program 
promotions in 2013 is provided in the Appendix (online 
at mja.com.au).7,10,11,13,14
All programs quantifi ed the benefi t of cervical screen-
ing using a fi gure resembling an estimate of relative risk 
reduction. Studies show that relative risk is not well under-
stood by the general public. If the aim of communication 
is to assist a woman to understand the likelihood of her 
individual benefi t, relative risk should be avoided in favour 
of frequency, absolute risk and the numbers needed to 
screen to avoid one death.13 A recent ethical assessment of 
persuasion in the context of health interventions endorsed 
provision of data, but warned against using misleading 
statistics, specifi cally those relating to relative risk.15
To be fully informed, women need to understand all 
the relevant benefi ts and harms of screening. Yet nei-
ther these nor the limitations of the test are addressed 
in most program materials. For the purposes of a clinical 
interaction, program communications do not encourage 
women to seek more or tailored information to assist 
decision making.
GPs work under conditions not conducive to 
informing about screening
GPs carry out around 80% of cervical screening in 
Australia.16 They are required to provide ethically sound 
care, which includes patient consent for interventions. 
However, current conditions do not encourage GPs to en-
sure that women are suffi ciently informed about Pap testing.
The role of a clinician includes offering recommen-
dations based on evidence and experience. The highly 
sensitive and personal nature of cervical screening means 
that persuasion to overcome an individual’s bias against 
a procedure, if it is likely to benefi t her, is ethically jus-
tifi able.15 However, such persuasion should occur in the 
context of providing as much information as the woman 
requires. GPs are expected to maximise the number of 
eligible women under their care who participate in screen-
ing. They have screening targets to meet, and incentive 
payments are made if they meet them. For some busy 
GPs, this may be a disincentive to initiate discussions 
about screening if there is a chance that fuller information 
may lead women to choose not to be screened.17,18 (The 
situation would be quite different, for example, if there 
were a Medicare item number for discussing cervical 
screening options rather than an incentive payment for 
screening.) Informing women is made more diffi cult by 
the complexity of screening epidemiology, in which GPs 
rarely have training.19,20
The combination of potentially misleading and per-
suasive public communications, the complexity of the 
evidence, screening targets, and the challenge of fi tting 
opportunistic screening into busy family practice appoint-
ments seems likely to undermine adequate provision of 
information. The extent of public material available (far 
greater than for many conditions that GPs manage) may 
reduce GPs’ perception of the need to inform women at 
the time of testing. The imperative to screen means that 
even an adequately informed woman may be labelled non-
compliant if she delays or refuses screening, and that her 
GP may be judged negatively against performance criteria.
Incomplete information is more likely to aff ect 
some groups of women than others
Women aged under 25 years are least likely to benefi t 
from screening, due to the very low incidence of cervi-
cal cancer in this age group. They are also most likely to 
experience harm from overtreatment, because of high 
rates of HPV and higher likelihood of future pregnan-
cies.4 An increasing proportion of younger women will 
be vaccinated against HPV, altering both the benefi t–risk 
relationship and their information needs. 
Socioeconomically disadvantaged women tend to have 
lower health literacy (http://www.abs.gov.au/ausstats/
abs@.nsf/mf/4233.0), higher rates of cervical cancer and 
lower screening rates.7 Additionally, Aboriginal and 
Torres Strait Islander women bear a disproportionately 
high burden, with a cervical cancer mortality rate fi ve 
times higher than the non-Indigenous rate.7 These groups’ 
particular needs are different because they may be more 
likely to benefi t from screening but may currently screen 
less than groups with lower incidence. A more tailored 
approach may help ensure that these groups receive the 
information they need to consent.
Addressing the ethical tension between 
population uptake and individual consent
Cervical screening is effective in preventing a propor-
tion of cervical cancers and is of benefi t to some women. 
However, this does not diminish the ethical requirement 
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to communicate suffi cient information to support valid 
consent to medical interventions. We have argued that 
current circumstances appear likely to undermine this 
requirement.
Alternatives to a persuasion-style public education 
campaign have been suggested. Such changes would re-
quire a shift in national policy to remove the requirement 
to increase screening participation in each 2-year cycle. 
Australia could follow the existing international prec-
edent for encouraging informed decision making about 
screening.21 Canadian guidelines propose to include rates 
of discussion of cervical screening as a program indic-
ator, along with rates of testing.22 In the UK, the National 
Health Service explicitly communicates the benefi ts and 
limitations of the Pap test: “It is your choice whether to 
have a cervical screening test or not. This leafl et aims 
to help you decide”.23 Proposals for screening, such as 
“consider an offer”, provide a framework for policymak-
ers and practitioners to use in letting individuals decide 
whether they want to make their own decision about 
screening or whether to hand that decision on to a well 
informed health care provider.24 There have been calls for 
screening information to be provided by a neutral body 
rather than a screening organisation.25 
Australians have already advocated for decision mak-
ing based on more explicit material information and indi-
vidual values.9 Such an approach may encourage women 
to have a conversation about the test with their health care 
providers, and encourage screeners to seek out suffi cient 
knowledge so they can adequately respond. An emphasis 
on providing information appropriate to heterogeneous 
groups and individuals could help ensure that women 
of limited literacy are informed along with other women 
with diverse concerns.
Thinking about the ethics of cancer screening means 
thinking about many dimensions of screening programs. 
We have only considered the ethical signifi cance of in-
forming. It is in the nature of cervical screening — which 
is both a population-based program and a personal clini-
cal service — that there may be tensions between the 
obligations of program managers to meet population 
objectives and the obligations of clinicians to provide ethi-
cally sound care for their patients. It would be diffi cult to 
argue that a patient should waive their interests in being 
informed about a procedure — or a clinician their duty 
to inform — because this would serve population-based 
goals. On the population side, there are generally held 
commitments to honesty in public communication and 
to ensuring legitimacy of state actions that are relevant to 
our consideration of how we should communicate about 
screening. This is not an easy balance to strike, but there 
would be value in public communications that encourage 
women to consider screening and to discuss this with 
their clinicians; and in fi nancial incentives and resources 
to support GPs discussing screening in detail with their 
patients, rather than the current incentives focused on 
participation rates. 
The current renewal of the NCSP provides an excellent 
opportunity to consider such options.
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